Polatuzumab vedotin, venetoclax, and an anti‐CD20 monoclonal antibody in relapsed/refractory B‐cell non‐Hodgkin lymphoma
American Journal of Hematology · 2024
DOI: 10.1002/ajh.27341 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Sam Yuen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Calvary Mater Newcastle Hospital, Waratah, New South Wales, Australia. Hauptthemen laut MEDLINE: Sulfonamides, Antineoplastic Combined Chemotherapy Protocols, Bridged Bicyclo Compounds, Heterocyclic, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Genentech, Inc, F. Hoffmann-La Roche Ltd.
Abstract (Originalsprache)
The Phase 2 portion of this study evaluated safety and efficacy of polatuzumab vedotin 1.8 mg/kg and venetoclax 800 mg, plus fixed‐dose obinutuzumab 1000 mg or rituximab 375 mg/m 2 in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or diffuse large B‐cell lymphoma (DLBCL), respectively. Patients with complete response (CR) or partial response (PR)/stable disease (FL) or CR/PR (DLBCL) at end of induction (EOI; six 21‐day cycles) received post‐induction therapy with venetoclax and obinutuzumab or rituximab, respectively. Primary endpoint was CR rate at EOI. Safety‐evaluable populations included 74 patients (FL cohort; median age 64 years; progression of disease within 24 months on first‐line treatment, 25.7%; FL International Prognostic Index 3–5, 54.1%; ≥2 previous therapies, 74.3%) and 57 patients (DLBCL cohort; median age 65 years; International Prognostic Index 3–5, 54.4%; ≥2 previous therapies, 77.2%). The most common non‐hematologic adverse events (mostly Grades 1–2) in the FL and DLBCL cohorts were diarrhea (55.4% and 47.4%, respectively) and nausea (47.3% and 36.8%); neutropenia was the most common Grades 3–4 toxicity (39.2% and 52.6%). Efficacy‐evaluable populations included patients treated at the recommended Phase 2 dose (FL, n = 49; DLBCL, n = 48). CR rates at EOI were 59.2% (FL) and 31.3% (DLBCL); median progression‐free survival was 22.8 months (95% confidence interval [CI], 14.5—not evaluable) and 4.6 months (95% CI, 3.6–8.1), respectively. Polatuzumab vedotin plus venetoclax and obinutuzumab/rituximab had acceptable safety in patients with R/R FL or DLBCL, with promising response rates in R/R FL, including high‐risk patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Calvary Mater Newcastle Hospital, Waratah, New South Wales, Australia.
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA.
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
- Princess Alexandra Hospital, Brisbane, Queensland, Australia.
- Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
- ASST Papa Giovanni XXIII, Bergamo, Italy.
ORCID-Profile: Tycel J Phillips
Förderung
- Genentech, Inc
- F. Hoffmann-La Roche Ltd
Zitieren
APA
Yuen, S., Phillips, T. J., Bannerji, R., Marlton, P., Gritti, G., Seymour, J. F., Johnston, A., Arthur, C., Dodero, A., Sharma, S., Hirata, J., Musick, L., & Flowers, C. R. (2024). Polatuzumab vedotin, venetoclax, and an anti‐CD20 monoclonal antibody in relapsed/refractory B‐cell non‐Hodgkin lymphoma. American Journal of Hematology. https://doi.org/10.1002/ajh.27341
Vancouver
Yuen S, Phillips TJ, Bannerji R, Marlton P, Gritti G, Seymour JF, et al. Polatuzumab vedotin, venetoclax, and an anti‐CD20 monoclonal antibody in relapsed/refractory B‐cell non‐Hodgkin lymphoma. American Journal of Hematology. 2024. doi:10.1002/ajh.27341
BibTeX
@article{Yuen2024,
author = {Yuen, Sam and Phillips, Tycel J and Bannerji, Rajat and Marlton, Paula and Gritti, Giuseppe and Seymour, John F and Johnston, Anna and Arthur, Christopher and Dodero, Anna and Sharma, Sunil and Hirata, Jamie and Musick, Lisa and Flowers, Christopher R},
title = {Polatuzumab vedotin, venetoclax, and an anti‐CD20 monoclonal antibody in relapsed/refractory B‐cell non‐Hodgkin lymphoma},
journal = {American Journal of Hematology},
year = {2024},
doi = {10.1002/ajh.27341}
}
EUVIMED